Sanofi’s Zaltrap Rejected by England’s Health-Cost Agency
This article is for subscribers only.
Sanofi’s cancer drug Zaltrap was rejected by England’s cost regulator, which said the drug isn’t cost effective even after the company offered a discount.
The treatment, also known as aflibercept, is clinically effective against colorectal cancer but exceeded the threshold at which a drug can be considered a cost-effective use of government funds, the National Institute for Health and Care Excellence said in a statement today. The agency, known as NICE, rejected Sanofi’s appeal of the decision, it said. NICE advises the National Health Service in England and Wales.